Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cash & Current Investments (2019 - 2023)

Historic Cash & Current Investments for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $310.4 million.

  • ADC Therapeutics' Cash & Current Investments fell 1849.84% to $310.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $310.4 million, marking a year-over-year decrease of 1849.84%. This contributed to the annual value of $466544.0 for FY2022, which is 9989.84% down from last year.
  • Latest data reveals that ADC Therapeutics reported Cash & Current Investments of $310.4 million as of Q3 2023, which was down 1849.84% from $347.51 recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Cash & Current Investments peaked at $439.2 billion during Q1 2021, and registered a low of $115.55 during Q1 2020.
  • Its 5-year average for Cash & Current Investments is $26.0 billion, with a median of $466544.0 in 2022.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 38008758027576.48% in 2021, then tumbled by 9999.99% in 2022.
  • ADC Therapeutics' Cash & Current Investments (Quarter) stood at $115.6 million in 2019, then tumbled by 99.57% to $494416.0 in 2020, then surged by 92771.65% to $459.2 million in 2021, then dropped by 28.91% to $326.4 million in 2022, then fell by 4.91% to $310.4 million in 2023.
  • Its Cash & Current Investments was $310.4 million in Q3 2023, compared to $347.51 in Q2 2023 and $326441.0 in Q1 2023.